GLOBAL IMMUNE TECHNOLOGIES INC.: 10-Q filed 2013-02-14

Name: GLOBAL IMMUNE TECHNOLOGIES INC.: 10-Q filed 2013-02-14
Creator: GLOBAL IMMUNE TECHNOLOGIES INC.

What GLOBAL IMMUNE TECHNOLOGIES INC. reported in its quarterly report filed 2013-02-14 (fiscal Q3 2012): 15 published measures, 71 facts as tagged in accession 0001144204-13-008833.

This filing

Form: 10-Q (quarterly report)
Filed: 2013-02-14
Fiscal period: fiscal Q3 2012
Accession: 0001144204-13-008833 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All GLOBAL IMMUNE TECHNOLOGIES INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2012-12-31	20,130	USD
At 2012-03-31	0	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2012-12-31	-1,117,259	USD
At 2012-03-31	-915,440	USD
At 2011-03-31	-850,298	USD
At 2010-03-31	-754,810	USD
At 2009-03-31	-693,790	USD
At 2008-03-31	-640,389	USD
At 2007-03-31	-506,933	USD
At 2006-03-31	-442,700	USD
At 2005-03-31	-369,181	USD
At 2004-03-31	-326,295	USD
At 2003-03-31	-274,894	USD
At 2002-03-31	-204,274	USD
At 2001-03-31	-12,196	USD
At 2000-03-31	240,881	USD
At 1999-03-31	86,295	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2012-12-31	20,130	USD
At 2012-03-31	0	USD
At 2011-12-31	0	USD
At 2011-03-31	0	USD
At 1999-03-31	296,970	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2012-10-01 to 2012-12-31	-197,286	USD	92
2012-04-01 to 2012-12-31	-207,619	USD	275
1999-04-01 to 2012-12-31	-2,619,120	USD	5024
2011-04-01 to 2012-03-31	-65,142	USD	366
2011-10-01 to 2011-12-31	-7,500	USD	92
2011-04-01 to 2011-12-31	-22,500	USD	275
2010-04-01 to 2011-03-31	-172,433	USD	365
2009-04-01 to 2010-03-31	-61,020	USD	365
2008-04-01 to 2009-03-31	-53,401	USD	365
2007-04-01 to 2008-03-31	-134,274	USD	366
2006-04-01 to 2007-03-31	-73,765	USD	365
2005-04-01 to 2006-03-31	-94,957	USD	365
2004-04-01 to 2005-03-31	-140,582	USD	365
2003-04-01 to 2004-03-31	-106,831	USD	366
2002-04-01 to 2003-03-31	-79,105	USD	365
2001-04-01 to 2002-03-31	-613,406	USD	365
2000-04-01 to 2001-03-31	-253,077	USD	365
1999-04-01 to 2000-03-31	-563,508	USD	366

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2012-04-01 to 2012-12-31	14,330	USD	275
1999-04-01 to 2012-12-31	-1,128,400	USD	5024
2011-04-01 to 2011-12-31	0	USD	275

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2012-04-01 to 2012-12-31	5,800	USD	275
1999-04-01 to 2012-12-31	851,560	USD	5024
2011-04-01 to 2011-12-31	0	USD	275

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2012-12-31	-4,670,072	USD
At 2012-03-31	-4,462,453	USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2012-10-01 to 2012-12-31	-197,286	USD	92
2012-04-01 to 2012-12-31	-207,619	USD	275
1999-04-01 to 2012-12-31	-1,698,613	USD	5024
2011-10-01 to 2011-12-31	-7,500	USD	92
2011-04-01 to 2011-12-31	-22,500	USD	275

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2012-12-31	20,130	USD
At 2012-03-31	0	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2012-12-31	1,137,389	USD
At 2012-03-31	915,440	USD

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2012-12-31	26,290,153	shares
At 2012-03-31	26,290,153	shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2012-12-31	4,542	USD
At 2012-03-31	4,542	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2012-10-01 to 2012-12-31	23,928	USD	92
2012-04-01 to 2012-12-31	23,928	USD	275
1999-04-01 to 2012-12-31	360,163	USD	5024
2011-10-01 to 2011-12-31	0	USD	92
2011-04-01 to 2011-12-31	0	USD	275

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

Period	Value	Unit	Days
2012-04-01 to 2012-12-31	0	USD	275
2011-04-01 to 2011-12-31	0	USD	275

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2012-04-01 to 2012-12-31	13,449	USD	275
1999-04-01 to 2012-12-31	231,503	USD	5024
2011-04-01 to 2011-12-31	0	USD	275

Inspect the source

Entity: GLOBAL IMMUNE TECHNOLOGIES INC. / CIK 0001105284
Captured: 2026-09-23 02:41 UTC
SEC response SHA-256: 8d0ae38865768bde5b4f2c5f32f5b691a6a3e5ec3be71ce129d2c50ed76f04a8

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001105284.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))